Fatal disseminated tuberculosis during treatment with ruxolitinib plus prednisolone in a patient with primary myelofibrosis: A case report and review of the literature

Yasuhiro Tsukamoto, Junichi Kiyasu, Mariko Tsuda, Motohiko Ikeda, Motoaki Shiratsuchi, Yoshihiro Ogawa, Yuji Yufu

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)

Abstract

A 73-year-old man with primary myelofibrosis (PMF) was being treated with hydroxyurea, which was changed to ruxolitinib treatment because of worsening constitutional symptoms. Although ruxolitinib rapidly induced relief, he developed a high-grade fever. A comprehensive fever work-up found no apparent cause of the fever, except for PMF. Therefore, we increased the dose of ruxolitinib and added prednisolone, which was gradually withdrawn with resolution of the fever. However, the patient subsequently developed disseminated tuberculosis and died eight months after initiation of ruxolitinib. Our case highlights the importance of assessing and monitoring the immune status of patients receiving ruxolitinib.

Original languageEnglish
Pages (from-to)1297-1300
Number of pages4
JournalInternal Medicine
Volume57
Issue number9
DOIs
Publication statusPublished - 2018

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Fingerprint Dive into the research topics of 'Fatal disseminated tuberculosis during treatment with ruxolitinib plus prednisolone in a patient with primary myelofibrosis: A case report and review of the literature'. Together they form a unique fingerprint.

Cite this